Drug firm Dr Reddy's Laboratories today said its net profit declined by 34.48% to Rs 165.87 crore in the fourth quarter ended March 31, 2011.
The company had posted a net profit of Rs 253.16 crore for the same period in the previous fiscal, Dr Reddy's Laboratories said in a filing to the Bombay Stock Exchange (BSE).
Net sales of the company for the quarter ended March 31, 2011, stood at Rs 1,318.71 crore, compared to Rs 1,152.37 crore for the corresponding quarter of the previous fiscal.
For the year ended March 31, 2011, the company posted a net profit of Rs 893.31 crore, compared to Rs 846.08 crore in the previous fiscal.
Net sales of the company for the year ended March 31, 2011, stood at Rs 5,218.04 crore, as against Rs 4,401.13 crore in the previous fiscal.
The Hyderabad-based firm posted a consolidated net profit of Rs 1,104 crore for the year ended March 31, 2011, compared to Rs 106.76 crore in the previous fiscal.
The company's consolidated net income from sales and services for the year stood at Rs 7,469.28 crore, compared to Rs 7,027.65 crore in the previous fiscal.
The company's board has recommended a final dividend of Rs 11.25 (225%) for the financial year 2010-11.
Shares of Dr Reddy's Laboratories were being quoted at Rs 1,652 apiece in late afternoon trade on the BSE today, up 3.08% from their previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app